---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-072543"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2023-06-20T23:59:59+00:00"
generated_at: "2026-06-13T21:10:20.930078+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Rezolute reports first use of RZ358 for insulinoma; patient achieved substantial hypoglycemia benefit

## Summary
- Patient with metastatic insulinoma and intractable hypoglycemia received RZ358 under compassionate use IND.
- Treatment began Q4 2022; patient continues therapy with substantial benefit and improved quality of life per Dr. Patti.
- Case presented as late-breaking abstract at ENDO 2023 on June 16, 2023; abstract published in Journal of Endocrine Society.
- This marks the first time Rezolute's RZ358 has been used for insulinoma indication.

## SEC filing metadata
- accession: 0001104659-23-072543
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2023-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465923072543/0001104659-23-072543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465923072543/tm2319018d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-072543
- JSON: https://secwatch.observer/filing/0001104659-23-072543.json
- Plain text: https://secwatch.observer/filing/0001104659-23-072543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.